UBS Group
DGX icon

UBS Group’s Quest Diagnostics DGX Stock Holding History

UBS Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$1.33M – 9625
2024
Q1 		$1.33M Buy
+10,000
New +$1.3M ﹤0.01% 4352
2021
Q1 		– Sell
-42,822
Closed -$5.1M – 9075
2020
Q4 		$5.1M Buy
+42,822
New +$5.22M ﹤0.01% 2427
2015
Q1 		– Sell
-400
Closed -$27K – 8916
2014
Q4 		$27K Buy
+400
New +$25.2K ﹤0.01% 7219

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

UBS Group's DGX Position: Q1 2026 in Review

UBS Group reduced its Quest Diagnostics (DGX) stake by 37% in Q1 2026, selling an estimated $80.1M and leaving 702,337 shares worth $138M. The position accounts for 0.02% of the portfolio, ranked #816.

UBS Group first reported a position in DGX in Q4 2014 and has held it in 46 quarters since. The position peaked at $193M in Q4 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • UBS Group held 702,337 shares of Quest Diagnostics worth $138M as of Q1 2026.
  • UBS Group sold 412,114 Quest Diagnostics shares in Q1 2026, an estimated $80.1M.
  • Quest Diagnostics made up 0.02% of UBS Group's portfolio in Q1 2026, its #816 holding.
  • UBS Group first reported a position in Quest Diagnostics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Quest Diagnostics position peaked at $193M in Q4 2025.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.